Abstract library

201 results for "Time of recurrence".
#1715 Recurrence of 6mm Rectal Neuroendocrine Tumor, 14 Years after Excision
Introduction: Rectal neuroendocrine tumours (NET) constitute 25% of all the digestive NET. Predictive factors of distant metastasis are: size greater than 1cm, high proliferative index and muscularis or lymphovascular invasion. In the absence of these criteria, some authors advocate there is no need for long-term follow-up.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#1674 Meta-Analysis of Recurrence after Curative Surgery of Pancreatic Neuroendocrine Tumors.
Introduction: Follow-up after curative surgery for pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence, however reliable recurrence rates are difficult to deduct from literature. Without this knowledge, appropriate follow-up regimens and indications for adjuvant treatment remain unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.
Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
#2241 Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and How?
Introduction: Pancreatic Neuroendocrine Tumors (pNETs) represent an increasing indication for pancreatic resection, but there are only few data about their possible recurrence after surgery.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Gaia Masini
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#421 Pelvic Carcinoid Tumor Recurrence Treated by Laparosocopic Ultrasonography Guided Laparoscopic Resection
Introduction: Minute retroperitoneal carcinoid tumor recurrences may be difficult to locate during surgery. A laparoscopic approach to re-resection is further hampered by the lack of tactile sense. Laparoscopic Ultrasonography (LUS) is a minimally invasive method which may compensate for the lack of palpation during laparoscopic surgery, and LUS allows for an evaluation of lesions beneath the visible surfaces. LUS is used in the pretherapeutic staging of upper GI tract cancer, and LUS can identify - and if necessary also biopsy - lesions less than 10 mm in diameter.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Henning O Nielsen
Authors: Nielsen H O, Mortensen M B, ...
#711 Risk of Recurrence in Patients with Neuroendocrine Tumors After R0-Resection
Introduction: Operative treatment with curative intention is still the corner stone of all recommendations. Risk of recurrence and time frame for follow-up is not well-defined.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Anja Rinke
Keywords: NEN, recurrence, grade, stage
#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors
Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team